The Commission aims to enhance the accountability of European organisations that process data by introducing the requirement for large employers and those that gather personal information through the course of their business to appoint data protection officers.
Under the proposals, the “patchwork” of data protection laws and reporting requirements across Europe will be replaced with a single set of rules for all 27 member states.
According to Viviane Reding, vice-president of the Commission, the reforms will eliminate unnecessary administrative burden for businesses, saving them around €2.3 billion per year.
She commented: “Businesses are worried because they are faced with many varied, sometimes contradictory data protection requirements, due to different national laws, due to different ways the national data protection authorities apply these laws, and they are also confronted with a load of notification requirements.
“This leads to legal uncertainty, to legal fragmentation and it makes it difficult for companies, most of all those innovative start-ups … t
From January 1 to April 15, most CPAs look like the accountant in Norman Rockwell’s famous Saturday Evening Post cover “Taxes” – hunched over for hours in an anything-but-ergonomic chair, spine curved like a shepherd’s hook over a tempest of papers, the only sustenance in sight is a forgotten pot of coffee wedged between old ledger books. But this isn’t the case for Stephanie Turner, CPA and supervisor at Faw Casson & Co., LLP of Dover, Delaware. By the time Turner hits the office, she’s already energized because she’s already hit the gym. She f 
Let’s start with the good news first. A report issued by the National Capital Association and PricewaterhouseCoopers found that venture capital investment in biotechnology grew 22 percent in 2011. And, now the bad news; initial funding for biotechnology startups seeking investment hit a 16 year low last year. The consensus among financial analysts is that life science investors are increasingly focusing on later stage companies because they carry less clinical and regulatory risks as compared with early stage ones. Put